Recruiting a foreign CEO: Christophe Weber and the shift to global management (2014)
A succession that severed management from nationality
The heart of this decision was that, to govern a business it had spread across the world, Takeda stepped into the internationalization of management itself. It had extended its operations globally by acquisition while failing to grow, from within, the executives to bind them together. Hasegawa and the board chose not to wait on in-house development but to bring in from outside a foreigner who knew the market well. Opening a management that founding family and lifers had carried for more than two centuries into a single post held regardless of nationality is what marks the character of this succession.
Recruiting from outside, however, sped the internationalization of the business while deferring the time it would take to raise the next chief at home. The Weber regime ran to about twelve years — a long tenure not easily changed even when results stalled. That Takeda entrusted the next CEO, in 2026, to another foreigner in Julie Kim is the flip side of the same fact. The fruit of globalization, and the unmet task of growing management talent in-house — the recruitment of a foreign chief left both behind at once.
Revenue and net margin, FY2009–FY2019
Revenue in ¥ bn (bars) and net margin in % (line), for the years around the decision. Shaded columns are FY2014 onwards — after it was taken.
Source: securities reports
Read the full dossier in Japanese →
The Japanese edition carries the complete record of this decision — the situation that forced it, the options weighed, what actually followed, and the sources behind every claim.
Other key decisions at Takeda Pharmaceutical
- 1993 Selection and concentration: cutting non-pharma to focus on prescription drugs (1993)
- 2008 Going all-in on North American prescription drugs: unwinding TAP and buying Millennium (2008)
- 2011 Buying Europe and emerging markets wholesale: the Nycomed acquisition (2011)
- 2019 Beyond the limits of in-house discovery: the ~$62 billion Shire acquisition (2019)
- 2020 Selling the Alinamin OTC business to Blackstone (2020)
Yen amounts are converted at the average rate of each figure’s own year — not today’s rate; the revenue chart is shown in yen. Exchange rates & sources — the full ¥/US$ table →
Disclaimer
- This page is provided for general information only and is not investment advice, nor a recommendation to buy or sell any security.
- Figures are compiled independently and include our own estimates, approximations and machine-processed data; we make no warranty as to their accuracy or completeness.
- Sources are primarily each company’s securities reports and other public filings, but errors and omissions may remain.
- Any use of this information is at the reader’s own risk. Past performance does not indicate future results.
- Company names, logos and other marks belong to their respective owners.
Data API
Takeda Pharmaceutical’s history, financials, executives and
shareholders are published as static JSON — no key, plain GET.
Full specification →
| Method | Endpoint | Returns |
|---|---|---|
| GET | /api/companies.json | All companies |
| GET | /api/4502/manifest.json | Resource index |
| GET | /api/4502/history.json | History overview |
| GET | /api/4502/timeline.json | Chronology |
| GET | /api/decisions.json | All management decisions (index) |
| GET | /api/4502/decisions.json | Management decisions (index) |
| GET | /api/4502/decisions/{slug}.json | One decision (full dossier) |
| GET | /api/4502/executives.json | Executives |
| GET | /api/4502/shareholders.json | Major shareholders |
| GET | /api/4502/financials.json | Financial statements |
| GET | /api/4502/financials-longterm.json | Long-term results |
| GET | /api/4502/segments.json | Business segments |
| GET | /api/4502/regions.json | Sales by region |
| GET | /api/4502/workforce.json | Workforce |